Nordion to host interactive TheraSphere educational session at the Society of Interventional Radiology Annual Scientific Meeting


Nordion a leading provider of products and services for the prevention, diagnosis and treatment of disease, will host an educational session called “TheraSphere test flight interactive: How to treat or should I treat?”at the Society for Interventional Radiology’s (SIR) Annual Scientific Meeting (13–18 April, New Orleans, USA). 

The session is part of SIR’s new Industry Interactive Program, developed to provide industry partners with the opportunity to host dynamic sessions that showcase the latest Interventional Radiology technologies and research, including TheraSphere, Nordion’s Y-90 microsphere treatment for hepatocellular carcinoma.

“Nordion’s session will feature hepatocellular carcinoma case presentations delivered by leading physicians to challenge expert panelists in their thinking, technique, and opinion on how, or if, they would proceed with TheraSphere treatment,” said Steve West, Nordion’s chief executive officer and chief operating officer, Targeted Therapies. “Nordion is always looking at ways to enhance the TheraSphere learning experience, and this interactive session is a great complement to our physician educational portfolio consisting of our Centers of Excellence, proctor training and preceptor programme.”

The TheraSphere interactive education sessionwill take place on Sunday, April 14 from 5:15–6:30 pm CDT, in the Ernest N Morial Convention Center, second floor, room 271. Scheduled panelists are:


  • Bulent Arslan, director Interventional Radiology, Rush University, USA


  • Matthew Johnson, professor Radiology and Surgery, Indiana University, USA


  • Daniel Sze, professor, Interventional Radiology, Stanford University, USA


Cases will be presented by physicians from hospitals across North America.

“The TheraSphere Test Flight Interactivesession will be a great forum for experienced TheraSphere users to share expertise and to assist colleagues in making informed decisions regarding the treatment of patients in different hepatocelluar carcinoma scenarios,” said Sze.

“Nordion’s participation in the new Industry Interactive Program demonstrates their continued commitment to work with SIR and with interventional radiologists to improve care for hepatocellular carcinoma patients.”